Malaysia Receives Antiviral Tecovirimat for MPOX
Health Minister Datuk Seri Dr. Dzulkefly Ahmad has announced that Malaysia has received a batch of antiviral Tecovirimat for mpox, a potentially dangerous viral infection. However, this medicine is reserved for high-risk groups to ensure effective treatment and prevention of the disease.
What is Tecovirimat?
- Tecovirimat is a medication used to treat smallpox, mpox, and cowpox.
- These infections are caused by viruses belonging to the same family, known as orthopoxviruses.
The high-risk groups identified by the minister are individuals with severe disease and a weakened immune system, who are more susceptible to the effects of mpox. This targeted approach ensures that those who need the medication the most receive it promptly.
Government Measures to Combat MPOX
Dr. Dzulkefly Ahmad emphasized the government’s commitment to preventing the spread of mpox in Malaysia. Stringent health screening measures have been implemented for inbound international travelers, with over six million individuals screened so far to detect any potential cases of the disease.
Despite the detection of a mpox case in Malaysia on Sept 17, the minister reassured the public that there have been no new cases reported. Continuous surveillance is in place to monitor the situation and prevent any further outbreaks.
Conclusion
The availability of antiviral medication like Tecovirimat plays a crucial role in managing and treating infectious diseases like mpox. By targeting high-risk groups and implementing proactive measures, Malaysia is taking steps to safeguard public health and prevent the spread of the disease within its borders.